IL-1 inhibition with anakinra was more effective than TNFi treatment for improving glycemic and inflammatory parameters in patients with rheumatoid arthritis and type 2 diabetes, say researchers writing in PLOS Medicine last month.
Patients with rheumatoid arthritis have a large comorbidity burden at the time of diagnosis, including chronic obstructive pulmonary disease (COPD), asthma and interstitial lung disease, but COPD is a particular concern, say researchers writing in Rheumatology this month.
Exposure to antibiotics increases the risk of developing rheumatoid arthritis, say researchers writing in the journal Rheumatology this month.
Total hip arthroplasty does not provide a clinically significant improvement over hemiarthroplasty in function and quality of life over 24 months, shows a NEJM study. The incidence of secondary procedures did not differ significantly between the two groups.
Vedolizumab proves to be superior to adalimumab for in achieving clinical remission and endoscopic improvement for ulcerative colitis, but not corticosteroid-free clinical remission.
Ustekinumab (Stelara, Janssen Biotech) was more effective at one year than placebo for inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis, NEJM study shows.
Ixekizumab was superior to adalimumab at 24 weeks in a head-to-head trial evaluating both skin and joint symptoms in patients with psoriatic arthritis and inadequate response to csDMARDs, say researchers writing in Annals of the Rheumatic Diseases last month.
The American Society for Bone and Mineral Research has developed clinical recommendations for the prevention of secondary fractures for patients aged 65 years and older after an initial hip or vertebral fracture. The recommendations were published in the Journal of Bone and Mineral Research last month.
Social support may be a prognostic factor for some joint-specific and general health outcomes after hip or knee replacement, say researchers writing in The Lancet Rheumatology this month.
Sjögren’s syndrome secondary to systemic lupus erythematosus (SLE) rises in frequency with age, affects around one-quarter of all people with systemic lupus, and, despite less internal organ involvement than in systemic lupus without Sjögren’s syndrome, is marked by a systemic inflammatory state with high levels of pro-inflammatory cytokines, say researchers writing in The Journal of Rheumatology this month.